drugset / Trial / NCT03371342

Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder

NCT03371342

Phase 1 Completed 30 enrolled Medy-Tox
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate the safety of MEDITOXIN in female subjects with idiopathic overactive bladder compared with BOTOX

Timeline

Start
2017-12-13
Primary completion
2018-05-31
Completion
2018-09-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic

Indications